| 5.15 -0.18 (-3.38%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.13  |
1-year : | 8.1 |
| Resists | First : | 6.11 |
Second : | 6.94 |
| Pivot price | 5.74  |
|||
| Supports | First : | 4.76 |
Second : | 3.96 |
| MAs | MA(5) : | 5.31 |
MA(20) : | 5.82 |
| MA(100) : | 4.03 |
MA(250) : | 3.07 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 20.3 |
D(3) : | 18.2 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 6.94 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRME ] has closed above bottom band by 13.9%. Bollinger Bands are 1.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.21 - 5.24 | 5.24 - 5.27 |
| Low: | 4.69 - 4.72 | 4.72 - 4.76 |
| Close: | 5.09 - 5.15 | 5.15 - 5.21 |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Sat, 25 Oct 2025
Prime Medicine (NASDAQ:PRME) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Thu, 23 Oct 2025
Prime Medicine (NASDAQ:PRME) Shares Down 10.9% - Here's What Happened - MarketBeat
Mon, 13 Oct 2025
Prime Medicine, Inc.'s (NASDAQ:PRME) 6.6% loss last week hit both individual investors who own 30% as well as institutions - simplywall.st
Wed, 08 Oct 2025
Prime Medicine (NASDAQ:PRME) Stock Price Up 11.6% - Should You Buy? - MarketBeat
Tue, 07 Oct 2025
Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Tue, 23 Sep 2025
Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now (PRME) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 178 (M) |
| Held by Insiders | 7.471e+007 (%) |
| Held by Institutions | 18.1 (%) |
| Shares Short | 19,120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9738e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 787.1 % |
| Return on Equity (ttm) | -47.4 % |
| Qtrly Rev. Growth | 4.96e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -57.99 |
| EBITDA (p.s.) | -5.59775e+007 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -100 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 29.25 |
| Dividend | 0 |
| Forward Dividend | 1.577e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|